Technology evaluation: AVI-4126, AVI BioPharma.
AVI BioPharma is developing AVI-4126, an antisense oligonucleotide targeted to c-myc mRNA for the potential treatment of restenosis, cancer and polycystic kidney disease. AVI-4126 is currently undergoing phase II clinical trials.
Stephens
Alick C
AC
Imperial College London, Department of Paediatrics, Faculty of Medicine, 2nd Floor Medical School, St Mary's Campus, Norfolk Place, Paddington London, W2 1PG UK. a.stephens@imperial.ac.uk
D000818:Animals; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000188:drug therapy / Q000235:genetics; D004353:Drug Evaluation, Preclinical; D016259:Genes, myc / Q000235:genetics* / Q000502:physiology; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D060172:Morpholinos; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010330:Patents as Topic; D007690:Polycystic Kidney Diseases / Q000188:drug therapy / Q000235:genetics; D013329:Structure-Activity Relationship
D009025:Morpholines; D060172:Morpholinos; D016376:Oligonucleotides, Antisense